M

Marinus Pharmaceuticals

D
MRNS
USD
0.075
(4.918%)
Market Closed
7,924.00
Volume
-2.03
EPS
-
Div Yield
-0.601504
P/E
88,134,460.80
Market Cap
Today
4.9180%
1 Week
14.286%
1 Month
19.403%
6 Months
-82.796%
12 Months
-77.224%
Year To Date
-85.294%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SPPI
(%)
USD
A
ACAD
0.11
(0.6736%)
USD
S
SAGE
0.32
(4.2161%)
USD
I
INSM
2.06
(2.8266%)
USD
AZN
AZN
0.32
(0.4072%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD
JNJ
JNJ
-1.31
(-0.7883%)
USD
AMGN
AMGN
3.02
(0.9071%)
USD
GILD
GILD
0.015
(0.0179%)
USD
PFE
PFE
-0.09
(-0.3025%)
USD

Title:
Marinus Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Do you need help or have a question?
Contact Us